Hospital Infusions Cost More. What Does That Tell an Employer About Savings?

The central observation in this episode is important and substantially correct: where an infusion is administered can materially affect what an employer health plan pays.

The discussion is also useful because it does not pretend that changing the site of care is simply a matter of finding a cheaper facility. The guests describe clinical restrictions, treatment initiation requirements, precertification, provider coordination, plan design, member communication and network constraints. Some therapies cannot be moved. Some can move only after initial treatment. Providers may resist changing the site. And intervention becomes more difficult once treatment is underway.

That makes infusion site-of-care economics a legitimate purchaser issue. It can also matter to stop-loss. A sufficiently expensive infusion may approach or exceed a specific attachment point, meaning that changing the claim amount can change whether the employer or stop-loss carrier bears particular dollars of cost. The episode appropriately draws attention to that connection, although the effect on future stop-loss premiums is a separate question.

The discussion becomes less useful when it moves from the existence of the problem toward its economic magnitude.

Early in the episode, listeners hear about the same infusion costing $1 million more at one location than another and later that some therapies can cost “10X” as much depending on site. These cases may exist. But exceptional price differences are not the same thing as the opportunity available to a typical purchaser.

A recent EBRI Issue Brief helps calibrate that distinction. Across 106 high-spending physician-administered outpatient drugs, hospital outpatient reimbursement was higher for 93. The median per-unit differential was 64% and the average was 102%.

That is a significant difference. It does not need a 10X example to make it consequential. Extreme anecdotes can make an otherwise well-supported proposition less informative. A 10X example demonstrates that extreme variation can occur. It does not establish the magnitude of the opportunity in that purchaser's plan. The distribution matters.

More importantly, neither a 64% differential nor a 10X differential tells an employer how much it can save.

The relevant purchaser question is conversion

How much of the measured opportunity survives the clinical and operational process required to reach it?

Some cases will not be clinically appropriate for movement. Some will be identified after the treatment pathway has already been established. Some may encounter provider, network or member constraints. In other cases, savings may come from renegotiating or repricing treatment without moving the patient at all.

Only after that process can a purchaser determine the replacement cost, the costs of the intervention and the portion of any reduction that it economically retains.

Stop-loss adds another layer. A lower infusion claim does not necessarily mean that the employer retained the entire avoided dollar. The result depends in part on where the claim falls relative to the employer's retained-risk boundary and any claimant-specific arrangements. Questions about whether lower claims later produce lower stop-loss premiums require a separate analysis.

The RHV episode spends considerable time describing why the conversion is difficult. What it does not do is connect those constraints back to the size of the opportunity. The result is an asymmetry: the listener receives highly visible examples of the upside and considerable detail about implementation, but little help estimating how much of the headline differential might survive the implementation process.

Evidentiary ceiling

The underlying proposition is strong. Hospital outpatient reimbursement for physician-administered drugs is often substantially higher than reimbursement in lower-cost settings, and the RHV discussion identifies credible mechanisms for reducing some of that spending.

What remains unresolved is the economically consequential question for an employer:

How much of the observed price differential is present in its population, how much is addressable, how much can be successfully captured, and how much ultimately remains as net purchaser savings?

A large price differential establishes an opportunity. It does not establish the size of the savings result.

EBRI Issue Brief Source: Fronstin, Paul, and M. Christopher Roebuck, “Location, Location, Location: Spending Differences for Physician-Administered Outpatient Medications by Site-of-Treatment,” EBRI Issue Brief, no. 666 (Employee Benefit Research Institute, September 24, 2026).